Teal Health secured $22 million for an at-home HPV cervical cancer screening device, positioning the company to scale its product and clinical evidence generation. The Series A was led by .406 Ventures with participation from multiple strategic and venture investors. At-home screening can reduce friction in cervical cancer detection pathways where access and adherence remain challenges. For regulators, device validation and usability studies often become decisive as companies move from pilot evidence into broader deployment. The funding indicates investor confidence in decentralized diagnostics that can pair with clinical follow-up workflows.